Recent reports from The New York Times and The Washington Post have revealed a troubling pattern of data suppression within the U.S. Food and Drug Administration (FDA). Career scientists at the agency have completed extensive, peer-reviewed safety studies on millions of vaccine recipients, only to have those findings withdrawn by political appointees before publication. This intervention prevents critical safety data from reaching the medical community and the public, raising serious questions about the integrity of America’s health surveillance systems.
The Suppressed Studies: Scale and Findings
The incidents in question involve significant datasets that had already been accepted for publication in reputable pharmacovigilance journals. In October, FDA scientists were directed to withdraw two major studies on COVID-19 vaccine safety from the journals Drug Safety and Vaccine. Shortly after, in February, top officials blocked the submission of safety abstracts for the shingles vaccine, Shingrix, to a major drug-safety conference.
These were not minor analyses. The scope of the research was substantial:
* Medicare Beneficiaries: One study examined the records of 7.5 million Medicare beneficiaries for 14 pre-specified adverse outcomes following 2023–2024 COVID-19 vaccinations. Using a self-controlled case-series design with up to 90 days of follow-up, the study found that only one signal—anaphylaxis occurring at roughly one per million Pfizer-BioNTech doses—exceeded statistical noise.
* Younger Demographics: A second study analyzed 4.2 million recipients aged six months to 64 years for more than a dozen outcomes. It identified rare signals for febrile seizures and myocarditis, both of which are already listed on the vaccine label.
* Shingrix Safety: The analysis of the shingles vaccine confirmed an elevated but low risk of Guillain-Barré syndrome, a finding that has been present in the package insert for years.
A Breakdown of Scientific Norms
The agency’s stated objection was that the authors “drew broad conclusions that were not supported by the underlying data.” In a functioning scientific ecosystem, this is a standard part of peer review. Reviewers typically request narrower language or revised discussion sections, resulting in manuscripts with more carefully bounded claims.
What is unprecedented here is the procedural anomaly: political appointees instructed staff scientists to withdraw manuscripts that had already been accepted by independent peer review. This bypasses the standard corrective mechanisms of science, replacing editorial refinement with administrative censorship.
The Asymmetry of Information
The impact of these withdrawals is compounded by a stark asymmetry in how different types of information are handled. In late November, a memo from the same FDA center linked the deaths of 10 children to COVID-19 vaccination—a claim the agency has not substantiated. This memo was released and widely covered.
In contrast, two studies showing that serious adverse effects are very rare across nearly 12 million doses were suppressed. This selectivity suggests a system where vaccine-critical claims move through low evidentiary thresholds, while reassuring safety findings are held to impossible standards. This pattern of “capture” extends beyond vaccine safety, now shaping which surveillance signals reach physicians and the public.
Implications for Public Health Infrastructure
This erosion of transparency meets its first major operational test in June, when the FIFA World Cup opens across North America. The tournament will host 48 teams, 11 U.S. cities, and over 6 million attendees over 39 days. This massive gathering coincides with a regional resurgence of measles:
* Mexico: More than 9,000 confirmed cases since February 2025.
* Canada: Lost its measles elimination status in November.
* United States: Vaccination coverage remains below the 95% threshold required for population immunity.
In ordinary times, this combination of high-density gatherings and rising infectious disease rates would demand heightened transparency. Instead, the Centers for Disease Control and Prevention (CDC) has lost approximately a quarter of its workforce in the past year. The agency has been editing its weekly journal under directive and operates within the same Department of Health and Human Services that directed the FDA to suppress vaccine-safety analyses.
The Clinician’s Dilemma
For medical professionals, this administrative opacity creates a dangerous blind spot. In Los Angeles, where the World Cup opens at SoFi Stadium, a respiratory cluster appearing in an emergency room would typically trigger alerts through three independent channels: local public health departments, the CDC’s Morbidity and Mortality Weekly Report (MMWR), and pathogen-specific dashboards. Each of these channels has been edited, paused, or compromised this year.
If a cluster turns out to be measles or H5N1 influenza, the question facing ICU attendants mirrors the one asked in June 1981 during the early days of the HIV crisis: Is the surveillance system still telling us the truth? The virtue of the system in 1981 was not that it understood the unfolding crisis—it did not—but that it was permitted to publish what it saw. Today, that permission is increasingly withdrawn.
Conclusion
When patients ask clinicians about vaccine safety, they rely on the assumption that the federal public health system is free to report its findings. However, with agency scientists unable to share completed safety analyses of millions of patients, doctors are left with incomplete information. As major global events test our public health infrastructure, the suppression of reassuring data undermines trust and hampers the ability of clinicians to provide accurate, evidence-based care.
